This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2022 Mar 1;74(4):752-753.

doi: 10.1093/cid/ciab522.

Early Monoclonal Antibody Administration Can Reduce Both Hospitalizations and Mortality in High-Risk Outpatients With Coronavirus Disease 2019 (COVID-19)

Jeffrey D Jenks¹, Saima Aslam¹, Lucy E Horton¹, Nancy Law¹, Ajay Bharti¹, Cathy Logan¹, Mahnaz Taremi¹, Florin Vaida², Michele Ritter¹; COVID-19 Clinic Team

Collaborators, Affiliations

Collaborators

COVID-19 Clinic Team:
Ajay Bharti, Nancy Law, Kathleen Bordeaux, Claudia Guerrero, Diana Paddock, Joseph Bautista, Claudia Medrano, Sarah Arend, Mackenzie Williams, Marvin Ochoa Vega, Charisse Montilla

Affiliations

¹ Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California, San Diego, La Jolla, California, USA.
² Division of Biostatistics and Bioinformatics, Department of Family Medicine and Public Health, University of California, San Diego, La Jolla, California, USA.

PMID: 34091664
PMCID: PMC8195212
DOI: 10.1093/cid/ciab522

Comment

Early Monoclonal Antibody Administration Can Reduce Both Hospitalizations and Mortality in High-Risk Outpatients With Coronavirus Disease 2019 (COVID-19)

Jeffrey D Jenks et al. Clin Infect Dis. 2022.

. 2022 Mar 1;74(4):752-753.

doi: 10.1093/cid/ciab522.

Authors

Jeffrey D Jenks¹, Saima Aslam¹, Lucy E Horton¹, Nancy Law¹, Ajay Bharti¹, Cathy Logan¹, Mahnaz Taremi¹, Florin Vaida², Michele Ritter¹; COVID-19 Clinic Team

Collaborators

COVID-19 Clinic Team:
Ajay Bharti, Nancy Law, Kathleen Bordeaux, Claudia Guerrero, Diana Paddock, Joseph Bautista, Claudia Medrano, Sarah Arend, Mackenzie Williams, Marvin Ochoa Vega, Charisse Montilla

Affiliations

¹ Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California, San Diego, La Jolla, California, USA.
² Division of Biostatistics and Bioinformatics, Department of Family Medicine and Public Health, University of California, San Diego, La Jolla, California, USA.

PMID: 34091664
PMCID: PMC8195212
DOI: 10.1093/cid/ciab522

No abstract available

PubMed Disclaimer

Comment on

Real-World Experience of Bamlanivimab for Coronavirus Disease 2019 (COVID-19): A Case-Control Study.
Kumar RN, Wu EL, Stosor V, Moore WJ, Achenbach C, Ison MG, Angarone MP. Kumar RN, et al. Clin Infect Dis. 2022 Jan 7;74(1):24-31. doi: 10.1093/cid/ciab305. Clin Infect Dis. 2022. PMID: 33846730 Free PMC article.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- PubMed Central